Greatbatch's EPS Meets, Net Tanks - Analyst Blog
February 27 2012 - 4:30AM
Zacks
Greatbatch’s (GB)
fourth-quarter fiscal 2011 adjusted (excluding one-time items)
earnings per share of 39 cents came in line with the Zacks
Consensus Estimate and trailed the year-ago adjusted earnings of 46
cents.
Profit (as reported) tumbled 59%
year over year to roughly $5.6 million (or 24 cents a share). The
New York-based company’s profits in the year-ago quarter were
boosted by a $9.5 million gain stemming from the settlement of a
lawsuit related to its Electrochem unit.
For the fiscal, adjusted earnings
of $1.68 a share also matched the Zacks Consensus Estimate while
surpassing the year-ago earnings of $1.51.
Revenues
Revenues rose 6% year over year to
$141.7 million in the fourth quarter, beating the Zacks Consensus
Estimate of $140 million. For the full year, sales climbed 7% year
over year to $568.8 million, also ahead of the Zacks Consensus
Estimate of $566 million.
Greatbatch saw solid double-digit
growth across its Vascular Access business and the Electrochem
division in the fourth quarter, in part offset by a weak
CRM/Neuromodulation business. Revenues for the quarter
benefited from roughly $3 million of medical devices sales and the
company’s takeover of Micro Power Electronics in late 2011. Foreign
currency movements contributed roughly $8 million to sales in
fiscal 2011.
Segment Review
Revenues from the larger Greatbatch
Medical division inched up 2% year over year to $121.3 million in
the fourth quarter. Within Greatbatch Medical, CRM/Neuromodulation
sales edged down 2% year over year to $77.2 million, impacted by
sustained pricing headwind and general sluggishness in the market.
Greatbatch expects revenues from this business to be lower in
first-half 2012 with a recovery expected in the back half.
Orthopedic revenues crept up 3% to
$31.6 million. Currency exchange swings did not have a material
impact on orthopedic sales in the quarter. Revenues from
Vascular Access soared 28% to $12.5 million on the back of growth
in the underlying market and increased market share.
Revenues from Greatbatch’s smaller
Electrochem segment, which offers high performance commercial
batteries, zoomed 44% year over year to $20.5 million. The
division’s sales were boosted by the contributions from the Micro
Power acquisition. Excluding the contribution, Electrochem sales
jumped 27%.
Margins
Gross margin, excluding inventory
step-up amortization related to acquisition, dipped to 31.7% from
33.4% a year ago. The decline is attributable to pricing
concessions made to large customers and an unfavorable mix.
Selling, general and administrative
expenses, as a percentage of sales, increased to 13.1% from 11.5%
in the prior-year quarter, as a result of higher legal and
consulting expenses, increased performance based compensation and
unfavorable currency exchange impact. Net research, development and
engineering costs (RD&E), as a percentage of sales, inched up
to 9% from 8.6% a year ago. Adjusted operating margin fell to 11.1%
from 13.3% a year ago.
Balance Sheet and Cash
Flows
Greatbatch ended the fiscal with
cash and cash equivalents of roughly $36.5 million, up 59% year
over year. Operating cash flows increased six-fold year over year
to $31 million in the fourth quarter (up 17% year over year to $90
million for the year).
The company repaid long-term debt
worth $40 million during fiscal 2011 and borrowed $45 million to
partly finance the Micro Power buyout. Its long-term debt increased
roughly 7% year over year to $236 million at the end of the
year.
Guidance and
Recommendation
Moving ahead, Greatbatch expects
revenues for fiscal 2012 in the band of $645 million to $665
million, a 13%-17% year-over-year growth. The forecast assumes
sales of up to $15 million from medical devices.
The company expects revenues from
CRM & Neuromodulation to be flat to down 3% in 2012. Vascular
access sales are forecast to climb 10%-20% while orthopedic
revenues are expected to increase 5%-15%. Revenues from the
Electrochem segment is expected to grow roughly 5% in 2012.
Greatbatch expects adjusted
earnings per share in the range of $1.75 to $1.85. Moreover,
Greatbatch foresees adjusted operating margin of 11.5%-12.5% for
the year. The current Zacks Consensus Estimates for revenue and
earnings per share for fiscal 2012 are $611 million and $1.82,
respectively.
Greatbatch is a leading producer
and supplier of batteries, capacitors and components used in
implantable medical devices. The company’s top customers include
Boston Scientific (BSX), Johnson &
Johnson (JNJ), Medtronic (MDT) and
St. Jude Medical (STJ).
Greatbatch has been acquiring
complementary businesses over the last few years. Its pipeline is
healthy with a number of products currently in development that are
expected to support growth in the long run.
We feel that operating results will
be supported by strength at the company’s Orthopedic business and
strategic investments. However, a soft CRM market and pricing
pressure remain as headwinds. Currently, we have an Outperform
rating on the stock.
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
GREATBATCH INC (GB): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024